Internal Medicine, Hematology & Oncology · Glendale, CA
NPI
1598758062
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1505 Wilson Ter, Suite 200
Glendale, CA, 91206
Phone (818) 409-0105
Groups this clinician bills Medicare through
Medicare paid, 2024
$7.8M
285,154 services
Medicare patients, 2024
1,041
Average age 75
Drug cost, 2024
$15.6M
3,271 prescriptions
Company payments, 2025
$7,192
From 52 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Boris Bagdasarian was code J1569 (injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg), 28,250 times for 78 patients. In total Boris Bagdasarian billed 285,154 services in 122 codes, and Medicare paid $7.8M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-03-13.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 28,250 | 78 | $35.65 | $1.0M |
| J9271 Injection, pembrolizumab, 1 mg | Office | 22,400 | 15 | $44.71 | $1.0M |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 18,838 | 158 | $0.09 | $1,699 |
| J0897 Injection, denosumab, 1 mg | Office | 14,638 | 65 | $20.55 | $301K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 8,490 | 53 | $36.71 | $312K |
| Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Office | 7,580 | 14 | $49.81 | $378K |
| J9267 Injection, paclitaxel, 1 mg | Office | 5,845 | 11 | $0.08 | $481 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 3,100 | 27 | $15.62 | $48K |
| 99214 Office E&M - Established | Office | 2,767 | 648 | $105.25 | $291K |
| 85025 Blood Count | Office | 2,446 | 626 | $7.61 | $19K |
| 36415 Venipuncture Blood Collection | Office | 2,184 | 655 | $8.63 | $19K |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2,010 | 14 | $31.59 | $64K |
| 99233 Hospital E&M - Subsequent | Facility | 1,845 | 247 | $97.49 | $180K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,800 | 24 | $0.07 | $135 |
| 96127 Behavioral Health Services | Office | 1,485 | 737 | $3.71 | $5,516 |
By year: 2022 $2.0M for 124,277 services; 2023 $2.8M for 161,870 services; 2024 $7.8M for 285,154 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,446 | 626 | $7.61 | $19K |
| 36415 Venipuncture Blood Collection | 2,184 | 655 | $8.63 | $19K |
| 80053 Clinical Chemistry | 958 | 259 | $10.35 | $9,915 |
Medicare prescription drug claims, 2024
In 2024, the drug Boris Bagdasarian prescribed most often to Medicare patients was Procrit (Epoetin Alfa), with 310 prescriptions and refills. In total Boris Bagdasarian wrote 3,271 Medicare prescriptions that cost $15.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Procrit Epoetin Alfa | 310 | 311 | 103 | $815K |
| Xtandi Enzalutamide | 155 | 155 | 26 | $2.1M |
| Letrozole Generic | 130 | 151 | 27 | $1,822 |
| Fulvestrant Generic | 125 | 125 | 17 | $110K |
| Kisqali Ribociclib Succinate | 113 | 113 | 20 | $1.7M |
| Lupron Depot Leuprolide Acetate | 109 | 152 | 21 | $292K |
| Ibrance Palbociclib | 100 | 100 | 11 | $1.6M |
| Anastrozole Generic | 98 | 142 | 22 | $782 |
| Zarxio Filgrastim-Sndz | 98 | 98 | 36 | $186K |
| Neulasta Pegfilgrastim | 97 | 97 | 27 | $583K |
| Tamoxifen Citrate Generic | 71 | 87 | 13 | $1,002 |
| Somatuline Depot Lanreotide Acetate | 70 | 70 | Under 11 | $903K |
| Lynparza Olaparib | 70 | 70 | Under 11 | $853K |
| Xgeva Denosumab | 65 | 65 | 11 | $205K |
| Promacta Eltrombopag Olamine | 62 | 65 | 11 | $789K |
Brand drugs: 1,806 claims; generic drugs: 1,465 claims; opioid claims: 51.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Boris Bagdasarian $7,192 ($7,192 in general payments such as food, travel and fees) from 52 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,012.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 22 | $1,012 |
| Janssen Biotech, Inc. JNJ | 21 | $668 |
| AstraZeneca Pharmaceuticals LP AZN | 21 | $581 |
| Merck Sharp & Dohme LLC MRK | 12 | $359 |
| Pfizer Inc. PFE | 14 | $305 |
| Astellas Pharma US Inc 4503.T | 8 | $237 |
| Incyte Corporation INCY | 9 | $231 |
| Caris MPI, Inc. | 6 | $225 |
| E.R. Squibb & Sons, L.L.C. BMY | 11 | $200 |
| Seagen Inc. PFE | 2 | $179 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.